Looking to invest in an ASX biotech share with the potential to become the next Telix Pharmaceuticals Ltd (ASX: TLX)?
You're not alone!
The S&P/ASX 200 Index (ASX: XJO) biopharmaceutical company has been going from strength to strength lately.
Just in the past few weeks, Telix made several announcements that sent the stock soaring.
First it announced positive results from its ProstACT SELECT clinical cancer trial. And just days later it reported on progress on approval for TLX250-CDx, its kidney cancer imaging agent, with the United States Food and Drug Administration (FDA).
So, just how well have shareholders in this ASX biotech share been faring?
Well, if you'd bought Telix shares one month ago you'd be sitting on a gain of 20% today.
If you'd bought at the start of 2024, you'd be up 78%.
And if you'd snapped up the ASX biotech share for a bargain $1.05 a share five years ago, you'd have watched those shares surge 1,606%.
Or enough to turn a $5,000 investment into $85,300!
Which bring us to Rory Hunter, portfolio manager of SG Hiscock's Medical Technology Fund.
Image source: Getty Images
The ASX biotech shares that could mimic Telix's success
The SG Hiscock's Medical Technology Fund will have done well with its Telix Pharmaceuticals holdings.
According to Hunter (courtesy of The Australian Financial Review):
We originally took a position [in Telix] back in 2019 and chief executive Christian Behrenbruch has delivered on all stated commercial milestones in a timely manner, which is a feat not often achieved among early stage biotechs.
Hunter remains moderately bullish on the outlook for the ASX biotech share. But he noted that in the case of this ASX biotech share, "The easy money has been made."
And he cautioned that "investors will need to stomach some volatility" with the Telix share price moving forward.
Though, as you can see on the price chart up top, that's something long-term shareholders in this ASX biotech share should already be well-familiar with.
When asked which stocks his fund holds that have the same explosive potential as Telix or Neuren Pharmaceuticals Ltd (ASX: NEU), Hunter pointed to Clarity Pharmaceuticals Ltd (ASX: CU6) and Dimerix Ltd (ASX: DXB).
He noted that Clarity Pharmaceuticals could replicate "Telix's success in radiotheranostics". While Dimerix could replicate "Neuren's success in rare diseases".
He added that with "assets in late-stage development", Dimerix was a potential M&A target.
Clarity, Hunter added, could also become a potential takeover target for its "exciting and compelling early-stage data".
The Clarity share price is already up a whopping 575% over 12 months.
The Dimerix share price has run even hotter. The ASX biotech share is up 817% over 12 months.
